PMID- 23217878
OWN - NLM
STAT- MEDLINE
DCOM- 20130628
LR  - 20121211
IS  - 1531-5037 (Electronic)
IS  - 0022-3468 (Linking)
VI  - 47
IP  - 12
DP  - 2012 Dec
TI  - Relapse of unilateral favorable histology Wilms' tumor: significant 
      clinicopathological factors.
PG  - 2210-5
LID - S0022-3468(12)00712-9 [pii]
LID - 10.1016/j.jpedsurg.2012.09.010 [doi]
AB  - PURPOSE: To evaluate the clinicopathological features that indicate relapse and 
      suggest a new risk based therapeutic strategy for unilateral Favorable Histology 
      Wilms Tumor (FH-WT). MATERIALS & METHODS: Thirty-three patients with unilateral 
      WT were treated in two institutions between 1986 and 2010. Twenty-eight patients 
      with FH-WT received primary nephrectomy according to the National Wilms' Tumor 
      Study (NWTS) or the Japanese Wilms' Tumor Study (JWiTS) protocol. Retrospective 
      analyses of the non-relapsed group (n=23) and the relapsed group (n=5) compared 
      age, gender, tumor laterality, tumor weight, initial tumor stage, known 
      histological subtype, chemotherapy (2 or 3 drugs), and any irradiation delivered. 
      Stages and histological subtypes of the tumors were re-evaluated according to the 
      Japanese staging system. RESULTS: Five of the twenty-eight tumors relapsed, and 
      one patient died. The initial staging (P=0.029) and the histological subtype 
      (P=0.003) were the only factors indicating relapse. Nine of the twenty-three 
      tumors were histologically classified as blastemal predominant subtype (BPT-WT). 
      Five relapsed. CONCLUSION: According to the basic Japanese therapeutic strategy, 
      all patients underwent a primary nephrectomy before chemotherapy. This study 
      suggests that the histological subtype pre-treatment "BPT-WT" should be included 
      as a strong indicator of poor prognosis. Such patients should be treated as a 
      high-risk group.
CI  - Copyright (c) 2012 Elsevier Inc. All rights reserved.
FAU - Aoba, Takeshi
AU  - Aoba T
AD  - Department of Pediatric Surgery, Shizuoka Children's Hospital, Shizuoka, Japan. 
      t2aoba@marianna-u.ac.jp
FAU - Urushihara, Naoto
AU  - Urushihara N
FAU - Fukumoto, Koji
AU  - Fukumoto K
FAU - Furuta, Shigeyuki
AU  - Furuta S
FAU - Fukuzawa, Hiroaki
AU  - Fukuzawa H
FAU - Mitsunaga, Maki
AU  - Mitsunaga M
FAU - Watanabe, Kentaro
AU  - Watanabe K
FAU - Yamoto, Masaya
AU  - Yamoto M
FAU - Miyake, Hiromu
AU  - Miyake H
FAU - Koyama, Mariko
AU  - Koyama M
FAU - Iwabuchi, Hideto
AU  - Iwabuchi H
FAU - Koike, Junki
AU  - Koike J
FAU - Tatsunami, Shinobu
AU  - Tatsunami S
FAU - Wakisaka, Munechika
AU  - Wakisaka M
FAU - Kitagawa, Hiroaki
AU  - Kitagawa H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pediatr Surg
JT  - Journal of pediatric surgery
JID - 0052631
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & dosage
MH  - Biopsy, Needle
MH  - Chemotherapy, Adjuvant
MH  - Child, Preschool
MH  - Cohort Studies
MH  - Combined Modality Therapy
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunohistochemistry
MH  - Infant
MH  - Japan
MH  - Kidney Neoplasms/mortality/*pathology/*therapy
MH  - Male
MH  - Neoplasm Invasiveness/pathology
MH  - Neoplasm Recurrence, Local/mortality/*pathology/therapy
MH  - Neoplasm Staging
MH  - Nephrectomy/*methods/mortality
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Survival Rate
MH  - Treatment Outcome
MH  - Wilms Tumor/mortality/*pathology/*therapy
EDAT- 2012/12/12 06:00
MHDA- 2013/07/03 06:00
CRDT- 2012/12/11 06:00
PHST- 2012/08/26 00:00 [received]
PHST- 2012/09/01 00:00 [accepted]
PHST- 2012/12/11 06:00 [entrez]
PHST- 2012/12/12 06:00 [pubmed]
PHST- 2013/07/03 06:00 [medline]
AID - S0022-3468(12)00712-9 [pii]
AID - 10.1016/j.jpedsurg.2012.09.010 [doi]
PST - ppublish
SO  - J Pediatr Surg. 2012 Dec;47(12):2210-5. doi: 10.1016/j.jpedsurg.2012.09.010.